FOR IMMEDIATE RELEASE: February 9, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) congratulates Lykos Therapeutics, formerly MAPS Public Benefit Corporation, on its announcement …
The stakes were high: This was the final phase — phase 3 — of MAPS’s study aiming to convince the FDA to approve MDMA-assisted therapy for PTSD. Doblin knew that if the participants didn’t see …
FOR IMMEDIATE RELEASE: December 13, 2023 MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from …
FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 …
It was at an IACP conference in Florida, the largest event for police officers in the world, that Gergerian met Rick Doblin, the former hippie and founder of Maps (an acronym in English for “Multidisciplinary …
MDMA has been gaining attention for its potential therapeutic applications. In recent years, MDMA therapy, particularly MDMA-assisted psychotherapy, has been a topic of extensive research, with MAPS’ …
The code was the result of a partnership between U.K.-based COMPASS Pathways and the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation to facilitate access and insurance …
Quote Originally appearing here (Archived)
FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …
The bill – HD 2137, by state Rep. Nicholas Boldyga – was introduced in January, apparently in response to reporting by The Washington Post and The New York Times regarding moves by the nonprofit …
Distinctions in Australian MDMA and Psilocybin Policy The Therapeutic Goods Administration (TGA) in Australia recently announced a new policy allowing for the limited use of psychedelic-assisted therapies …
